These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12748448)

  • 41. Hepatic Injury without Granulomatous Formation Associated with Intravesical Bacillus Calmette-Guérin Therapy.
    Okano H; Asakawa H; Nose K; Tsuruga S; Tochio T; Kumazawa H; Isono Y; Tanaka H; Matsusaki S; Sase T; Saito T; Mukai K; Nishimura A; Usui M; Baba Y; Murata T
    Intern Med; 2019 May; 58(10):1429-1432. PubMed ID: 30626835
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
    Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
    J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Miliary Mycobacterium bovis induced by intravesical bacille Calmette-Guérin immunotherapy.
    McParland C; Cotton DJ; Gowda KS; Hoeppner VH; Martin WT; Weckworth PF
    Am Rev Respir Dis; 1992 Nov; 146(5 Pt 1):1330-3. PubMed ID: 1443892
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Left Anterior Descending Coronary Artery and Multiple Peripheral Mycotic Aneurysms Due to Mycobacterium Bovis Following Intravesical Bacillus Calmette-Guerin Therapy: A Case Report.
    Duvnjak P; Laguna M
    J Radiol Case Rep; 2016 Aug; 10(8):12-27. PubMed ID: 27761190
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ENDOPHTHALMITIS IN A PATIENT TREATED WITH BACILLUS CALMETTE-GUÉRIN IMMUNOTHERAPY.
    Vadboncoeur J; Olivier S; Soualhine H; Labbé AC; Bélair ML
    Retin Cases Brief Rep; 2018 Fall; 12(4):326-330. PubMed ID: 27893591
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epididymo-orchitis caused by intravesically instillated bacillus Calmette-Guérin: genetically proven using a multiplex polymerase chain reaction method.
    Harada H; Seki M; Shinojima H; Miura M; Hirano T; Togashi M
    Int J Urol; 2006 Feb; 13(2):183-5. PubMed ID: 16563148
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Disseminated Granulomatous Disease from Intravesical Instillation of Bacillus Calmette-Guerin.
    Ghafouri SAR; Brun A; Bhalla R; Margulies C; Skole K
    Case Rep Oncol Med; 2018; 2018():8280527. PubMed ID: 30245898
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Poncet's disease after the intravesical instillation of Bacillus Calmette-Guérin (BCG): a case report.
    Sampaio PCM; Lira YG; Ribeiro HYU; de Paula Moreira F; Gadelha MSM; da Cruz SFS
    BMC Res Notes; 2017 Aug; 10(1):416. PubMed ID: 28821265
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systemic granulomatous reaction secondary to treatment of bladder cancer with bacillus calmette-guerin.
    Valentini CG; Bozzoli V; Larici AR; Larocca LM; Delogu G; Leone G; Pagano L
    Mediterr J Hematol Infect Dis; 2012; 4(1):e2012040. PubMed ID: 22811789
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The possible influence of antibiotics on results of bacillus Calmette-Guérin intravesical therapy for superficial bladder cancer.
    van der Meijden PM; van Klingeren B; Steerenberg PA; de Boer LC; de Jong WH; Debruyne FM
    J Urol; 1991 Aug; 146(2):444-6. PubMed ID: 1856950
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Spondilodyscitis with medullary and spinal abscess caused by Bacillus Calmette-Guérin (BCG)].
    Lara-Oya A; Ramírez-Taboada J; Arenas-Miras Mdel M; Rodríguez-Granger J
    Rev Chilena Infectol; 2015 Dec; 32(6):706-9. PubMed ID: 26928510
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bacillus Calmette-Guérin strain differences as the basis for immunotherapies against bladder cancer.
    Miyazaki J; Onozawa M; Takaoka E; Yano I
    Int J Urol; 2018 May; 25(5):405-413. PubMed ID: 29506322
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [A Case Diagnosed as Iatrogenic Vesical Tuberculosis 4 Years after Intravesical Immunotherapy Using Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Carcinoma].
    Kudo T; Iwasa N; Maeda S; Mitarai S
    Kansenshogaku Zasshi; 2016 Nov; 90(6):809-13. PubMed ID: 30277373
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Tuberculosis induced by Bacillus Calmette-Guerin immuno-prophylaxis -- case study].
    Frickmann H; Jungblut S; Hanke P; Bargon J
    Pneumologie; 2004 Nov; 58(11):773-6. PubMed ID: 15534773
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma.
    Kaasinen E; Rintala E; Pere AK; Kallio J; Puolakka VM; Liukkonen T; Tuhkanen K
    J Urol; 2000 Jul; 164(1):47-52. PubMed ID: 10840422
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reiter's syndrome postintravesical Bacillus Calmette-Guérin instillations.
    Ng KL; Chua CB
    Asian J Surg; 2017 Apr; 40(2):163-165. PubMed ID: 25183290
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    Williams A; Arnold B; Gwynne-Jones DP
    Arthroplast Today; 2019 Dec; 5(4):416-420. PubMed ID: 31886382
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tuberculosis complications after BCG treatment for urinary bladder cancer.
    Naudžiūnas A; Juškaitė R; Žiaugrytė I; Unikauskas A; Varanauskienė E; Mašanauskienė E
    Medicina (Kaunas); 2012; 48(11):563-5. PubMed ID: 23455890
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long term protection in bladder cancer following intralesional immunotherapy.
    Reichert DF; Lamm DL
    J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
    Martínez-Piñeiro L; Portillo JA; Fernández JM; Zabala JA; Cadierno I; Moyano JL; Solsona E; Unda M; Beardo P; Rodríguez-Molina J; Chantada V; Palou J; Muntañola P; Alonso Dorrego JM; Pérez-Garcia FJ; Silva JM; Chesa N; Montesinos M; Ojea A; Madero R; Martínez-Piñeiro JA
    Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.